Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Semi-automated closed system manufacturing of lentivirus gene-modified haematopoietic stem cells for gene therapy

20 Oct 2016

Abstract excerpt

Abstract Haematopoietic stem cell (HSC) gene therapy has demonstrated potential to treat many diseases. However, current state of the art requires sophisticated ex vivo gene transfer in a dedicated Good Manufacturing Practices facility, limiting availability. An automated process would improve the availability and standardized manufacture of HSC gene therapy. Here, we develop a novel program for semi-automated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to RNA Interference and Gene Delivery
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 27762266
DOI: 10.1038/ncomms13173

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Semi-automated closed system manufacturing of lentivirus gene-modified haematopoietic stem cells for gene therapyPMID 27762266Read ↗

Clinical hematopoietic stem cell-based gene therapySemantic proximity Read ↗

Ex Vivo Expansion of Hematopoietic Stem and Progenitor Cells from Human Mobilized Peripheral Blood for Gene Therapy ApplicationsSemantic proximity Read ↗

Hematopoietic stem cell gene therapy: The optimal use of lentivirus and gene editing approachesSemantic proximity Read ↗

Preclinical Development of a Hematopoietic Stem and Progenitor Cell Bioengineered Factor VIII Lentiviral Vector Gene Therapy for Hemophilia ASemantic proximity Read ↗

Advancements in Hematopoietic Stem Cell Gene Therapy: A Journey of Progress for Viral TransductionSemantic proximity Read ↗

Efficient Ex Vivo Engineering and Expansion of Highly Purified Human Hematopoietic Stem and Progenitor Cell Populations for Gene TherapySemantic proximity Read ↗

Successes and challenges in clinical gene therapySemantic proximity Read ↗

Enhancing Lentiviral and Alpharetroviral Transduction of Human Hematopoietic Stem Cells for Clinical ApplicationSemantic proximity Read ↗

Targeted, safe, and efficient gene delivery to human hematopoietic stem and progenitor cells in vivo using the engineered AVID adenovirus vector platformSemantic proximity Read ↗

Improving Gene Therapy Efficiency through the Enrichment of Human Hematopoietic Stem CellsSemantic proximity Read ↗

Editing human hematopoietic stem cells: advances and challengesSemantic proximity Read ↗

Genetic Engineering and Manufacturing of Hematopoietic Stem CellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.